Supplementary table II - Efficacy and tolerance of dupilumab in obese patients with moderate-to-severe atopic dermatitis. Dupuis et al

Published: 18 December 2023| Version 1 | DOI: 10.17632/8mbpb6snwz.1
Contributor:
Joséphine Dupuis

Description

Supplementary table II: Dupilumab dose optimization and discontinuation.

Files

Institutions

Universite de Lille

Categories

Descriptive Table

Licence